For a small biotech, the most expensive word in European market access is often not “no”. It is “later”. Belgium’s new Early and Equitable Fast Access (EEFA) pathway aims to …
Category:
Reimbursement
-
-
What a Dutch population study of MammaPrint and Oncotype DX reveals about access, adoption and chemotherapy decisions A short evidence blog from Odelle Technology 9% → 25% → 37% Use …
-
Why KVÅ Procedure Reimbursement Matters in Sweden KVÅ procedure reimbursement is one of the most powerful—but often misunderstood—mechanisms in the Swedish healthcare system. What appears to be a simple six-character …